Ms. magazine  -- more than a magazine a movement

SIGN UP FOR MS. DIGEST, JOBS, NEWS AND ALERTS

FEMINIST WIRE NEWSBRIEFS

ABOUT
SEE CURRENT ISSUE
SHOP MS. STORE
MS. IN THE CLASSROOM
FEMINIST DAILY WIRE
FEMINIST RESOURCES
PRESS
JOBS AT MS.
READ BACK ISSUES
CONTACT
RSS (XML)
 
feminist wire | daily newsbriefs

December-12-01

New Drug May Be Effective in Treating Breast Cancer

Studies presented at the San Antonio Breast Cancer Symposium indicate that a new class of hormone therapy may replace Tamoxifen in the treatment of certain types of breast cancers. In post-menopausal women with locally advanced or metastatic breast cancer and also in post-menopausal women with estrogen-receptor and HER-2 positive breast cancer, data suggests that Femara, a drug developed by the Swiss Pharmaceutical company Novartis, is more effective than the commonly used Tamoxifen in shrinking tumor growth. More importantly, in randomized-double blind studies, paid for in part by Novartis, Femara offered a better survival advantage than Tamoxifen. Side effects are essentially the same for both drugs. Femara is an aromatase inhibitor, a drug that prevents the hormone androgen from being converted to estrogen. Tamoxifen is an anti-estrogen, a drug that blocks the effects of already-existing estrogen from exerting its effects at the cellular level.

Research indicates that all breast cancer is not created equal. Future treatment plans will become more and more individually tailored as scientific advancements reveal more about the particulars of certain types of breast cancer. Therefore, it is critical that basic research and clinical trials continue in order to provide maximal therapeutic options for all women.

The Feminist Majority Foundation has launched an emergency campaign for mifepristone (also known as RU-486 and the abortion pill), an important anti-progesterone drug that blocks the effects of progesterone, at the cellular level. Preliminary studies indicate that mifepristone may be effective in treating certain types of breast cancer. Much basic research and clinical trials have come to a standstill however because anti-abortion forces have made it extremely difficult for scientists to even procure the drug to explore its exciting non-abortion medical potential.

Media Resources: Novartis; Associated Press, 12/11/01; Feminist Majority Foundation


© Feminist Majority Foundation, publisher of Ms. magazine

If you liked this story, consider making a tax-deductible donation to support Ms. magazine.

 

 

Send to a Friend
Their
Your
Comments
(optional)


More Feminist News

5/27/2015 California Passes Reproductive FACT Act - The California State Assembly passed the Reproductive Freedom, Accountability, Comprehensive Care and Transparency (FACT) Act yesterday. AB 775, or the FACT Act, passed 48-25 in a vote, and requires that unlicensed facilities in California that provide pregnancy-related services disclose that they are not licensed medical providers. . . .
 
5/26/2015 Ireland Votes Overwhelmingly to Legalize Same-Sex Marriage - Over the weekend, the people of Ireland voted overwhelmingly to pass a national referendum legalizing same-sex marriage. Ireland became the first country in the world to pass marriage equality through popular vote on Friday. . . .
 
5/26/2015 Maryland Governor Will Not Veto LGBT Rights Bills - Maryland Governor Larry Hogan (R) has announced that he will not veto two pieces of legislation protecting LGBT rights passed by the state legislature in March, meaning they will soon become law. The Maryland General Assembly passed SB 743 / HB 862 and SB 416 / HB 838 by wide margins and with bipartisan support on March 24, after which both were sent to the Governor's desk. . . .